Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN)

Representative David Taylor (R-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on February 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on January 16th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.

Amgen Stock Down 1.8%

Shares of NASDAQ AMGN opened at $338.59 on Wednesday. The stock has a market capitalization of $182.32 billion, a PE ratio of 26.17, a P/E/G ratio of 3.03 and a beta of 0.46. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The firm has a fifty day moving average of $332.76 and a 200-day moving average of $310.04. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $353.25.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company earned $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.0%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Morgan Stanley lowered their price target on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Scotiabank started coverage on Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price for the company. Wells Fargo & Company lifted their target price on Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Finally, HSBC reiterated a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $342.45.

Hedge Funds Weigh In On Amgen

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Laurel Wealth Advisors LLC increased its position in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the period. Norges Bank bought a new position in shares of Amgen during the second quarter worth about $1,663,726,000. Capital World Investors increased its holdings in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. Vanguard Group Inc. increased its holdings in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the period. Finally, National Bank of Canada FI lifted its position in Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat expectations — Amgen reported $5.29 EPS vs. consensus $4.76 and revenue of $9.87B vs. $9.46B; revenue rose ~8.6% YoY, driven by higher drug volumes. AMGEN Reports Fourth Quarter and Full Year 2025 Financial Results (Press Release/Slides)
• Positive Sentiment: Analysts and media note the quarter beat Street estimates on higher sales and a lower effective tax rate — items that helped EPS performance. Reuters: Amgen quarterly results beat Street estimates
• Neutral Sentiment: FY‑2026 guidance was reiterated/updated to an EPS range of 21.600–23.000 and revenue guidance roughly $37.0B–$38.4B; the range overlaps consensus but is wide, which may leave investors wanting clearer directional guidance.
• Neutral Sentiment: Market commentary and conference coverage remain generally constructive on Amgen’s pipeline and longer‑term prospects (e.g., positive remarks from commentators at the JPMorgan Healthcare Conference), supporting medium‑term fundamentals. Jim Cramer / Pipeline Commentary
• Negative Sentiment: Some of the reported earnings strength reflected lower net unrealized losses on equity investments and a lighter tax burden rather than pure operational margin expansion; that can temper how investors value the beat relative to recurring cash‑earnings. WSJ: Amgen logs higher Q4 revenue, lower unrealized losses
• Negative Sentiment: Broader market dynamics — rotation out of certain sectors and post‑earnings profit‑taking — likely amplified the selloff despite the beat; trading volumes were elevated on the move. Zacks: Markets rotate back out of tech after Q4 earnings

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This represents a 30.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.69% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.